UNITED STATESSECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORTPURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 31, 2017

E. I. du Pont de Nemours and Company(Exact Name of Registrant as Specified in Its Charter)

Delaware 1-815 51-0014090

(State or Other Jurisdiction (Commission (I.R.S. EmployerOf Incorporation) File Number) Identification No.)

974 Centre RoadWilmington, Delaware 19805

(Address of principal executive offices)

Registrant’s telephone number, including area code: (302) 774-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the followingprovisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On March 31, 2017, pursuant to commitments given to the European Commission in connection with its conditional approval of the merger of equalstransaction of E. I. du Pont de Nemours and Company (“ DuPont ”) and The Dow Chemical Company (“ Dow ”), DuPont and FMC Corporation (“ FMC ”) enteredinto a definitive Transaction Agreement (the “ Transaction Agreement ”). On the terms and subject to the conditions set forth in the Transaction Agreement,(i) FMC has agreed to purchase certain assets relating to DuPont’s Crop Protection business and research and development organization (collectively, the “Divested Ag Business ”) and (ii) DuPont has agreed to purchase certain assets relating to FMC’s Health and Nutrition business segment, excluding its Omega-3products (the “ Acquired H&N Business ”) (collectively, the “ Transactions ”). Additionally, FMC will pay DuPont $1.2 billion in cash (subject to certainadjustments set forth in the Transaction Agreement), which reflects the difference in value between the divested businesses. DuPont will retain accounts receivableand accounts payable associated with the Divested Ag Business, with an expected net value of $425 million.

Specifically, DuPont will divest its Cereal Broadleaf Herbicides and Chewing Insecticides portfolios. DuPont will also divest its Crop Protection researchand development pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs, which DuPont will continue to develop andbring to market, and excluding personnel needed to support marketed products and R&D programs that will remain with DuPont.

The completion of the Transactions is subject to the satisfaction or waiver of certain conditions, including (i) the closing of the merger with Dow prior to orsubstantially concurrently with the closing of the Transactions, (ii) approval of FMC as the buyer of the Divested Ag Business by certain governmental entities,including the European Commission and the U.S. Department of Justice, (iii) receipt of certain domestic and foreign approvals under competition laws, (iv) theabsence of governmental restraints or prohibitions preventing the consummation of either of the Transactions or that, together with the Divestiture Actions (asdefined below) undertaken would reasonably be expected to have a Substantial Detriment (as defined below) and (v) certain other customary closing conditions.

The Transaction Agreement contains mutual customary representations and warranties made by each of DuPont and FMC, and also contains mutualcustomary pre-closing covenants. The Transaction Agreement contains certain termination rights for each of DuPont and FMC, including in the event that theTransactions are not consummated on or before the date that is nine months from the date hereof, subject to each party having the right to unilaterally extend thetermination date of the Transaction Agreement until the date that is twelve months from the date hereof in the event that the regulatory closing conditions have notbeen satisfied.

The Transaction Agreement provides that each of DuPont and FMC is required, and shall cause its subsidiaries, to take all actions necessary to obtaingovernmental, regulatory and third party approvals, related to the Transactions subject to limited exceptions, including that DuPont is not required to take certainspecified actions to obtain regulatory approval with respect to the acquisition of the Acquired H&N Business (“ Divestiture Actions ”) that would reasonably belikely to result in the one-year loss of revenues to DuPont, Dow, DowDuPont Inc., their subsidiaries or the Acquired H&N Business in excess of $350 million inthe aggregate (based on fiscal year 2016 annual revenues) (a “ Substantial Detriment ”).

DuPont expects to close the Transactions in the fourth quarter of 2017.

On March 31, 2017, DuPont entered into an amendment (“ Amendment No. 1 ”) to the Agreement and Plan of Merger (the “ Merger Agreement ”), dated asof December 11, 2015, with Dow.

Amendment No. 1 extends the Outside Date (as defined in the Merger Agreement) from June 15, 2017 to August 31, 2017 and amends the MergerAgreement to provide that DuPont shall not agree to any Divestiture Action relating to the Acquired H&N Business that would constitute a Substantial Detriment.

DuPont and Dow expect to close the merger in August 2017, subject to satisfaction of customary closing conditions, including receipt of regulatoryapprovals.

Other than as expressly modified pursuant to Amendment No. 1, the Merger Agreement, which was previously filed as Exhibit 2.1 to the Current Report onForm 8-K filed with the Securities and Exchange Commission by DuPont on December 11, 2015, remains in full force and effect as originally executed onDecember 11, 2015. The foregoing description of Amendment No. 1 does not purport to be complete and is subject to, and qualified in its entirety by, the full textof Amendment No. 1 attached hereto as Exhibit 2.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

On March 31, 2017, DuPont issued a press release in connection with the Transactions (a copy of which is furnished herewith as Exhibit 99.1 and isincorporated by reference herein) and issued a joint press release with Dow in connection with Amendment No. 1 (a copy of which is furnished herewith as Exhibit99.2 and is incorporated by reference herein). Also furnished herewith as Exhibit 99.3 is a presentation to be used in whole or in part during interactions withinvestors. The presentation will be available on the investor center at www.dupont.com.

The information contained in Item 7.01, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 of this report on Form 8-K shall not be deemed “filed” forpurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), orotherwise subject to the liability of that section, and it will not be incorporated by reference into any registration statement or other document filed by the Registrantunder the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description of Exhibit

2.1

Amendment No. 1, dated March 31, 2017, to the Agreement and Plan of Merger, dated as of December 11, 2015 by and among E. I. du Pont deNemours and Company, The Dow Chemical Company, Diamond Merger Sub, Inc., Orion Merger Sub, Inc. and Diamond-Orion HoldCo, Inc. (n/k/aDowDuPont Inc.)

99.1 Press Release, March 31, 2017, issued by E. I. du Pont de Nemours and Company.

99.2 Joint Press Release, March 31, 2017, issued by E. I. du Pont de Nemours and Company and The Dow Chemical Company.

99.3

Summary of Transactions with FMC: Divestiture of Certain Crop Protection Assets and Acquisition of FMC’s Health & Nutrition Business

Cautionary Notes on Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected futurebusiness and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,”“will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, todifferent degrees, uncertain, such as statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the “DowDuPont Merger ”) and the proposed transaction with FMC and the anticipated benefits thereof. These and other forward-looking statements, including thefailure to consummate the DowDuPont Merger or the proposed transaction or to make or take any filing or other action required to consummate such transactionsin a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differmaterially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) thecompletion of the DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated taxtreatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition,losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s or the Acquired H&NBusiness’s operations and other conditions to the completion of the DowDuPont Merger and the proposed transaction, (ii) the possibility that the DowDuPontMerger and the proposed transaction may not close, including because the various approvals, authorizations and declarations of non-objections from certainregulatory and governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely basis orotherwise, including that these regulatory or governmental authorities may not approve of FMC as an acceptable purchaser of the Divested Ag Business inconnection with the proposed transaction or may impose conditions on the granting of the various approvals, authorizations and declarations of non-objections,including requiring the respective Dow, DuPont and FMC businesses, including the Acquired H&N Business (in the case of DuPont) and the Divested Ag Business(in the case of FMC), to divest certain assets if necessary to obtain certain regulatory approvals or otherwise limiting the ability of the combined company tointegrate parts of the Dow and DuPont businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to integrate the Acquired H&NBusiness successfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont Merger or the proposedtransaction that could be instituted against DuPont or its directors, (v) the risk that disruptions from the DowDuPont Merger or

the proposed transaction will harm DuPont’s business, including current plans and operations, (vi) the ability of DuPont to retain and hire key personnel,(vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the DowDuPont Merger or the proposedtransaction, (viii) uncertainty as to the long-term value of DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions,(x) legislative, regulatory and economic developments, (xi) potential business uncertainty, including changes to existing business relationships, during thependency of the DowDuPont Merger or the proposed transaction that could affect DuPont’s financial performance, (xii) certain restrictions during the pendency ofthe DowDuPont Merger or the proposed transaction that may impact DuPont’s ability to pursue certain business opportunities or strategic transactions and(xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’sresponse to any of the aforementioned factors. These risks, as well as other risks associated with the DowDuPont Merger or the proposed transaction, are or will bemore fully discussed in (1) DuPont’s most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and(3) the joint proxy statement/prospectus included in the Registration Statement filed with the SEC in connection with the DowDuPont Merger. While the list offactors presented here is, and the list of factors presented in the relevant Form 10-K, 10-Q and 8-K reports and the Registration Statement are, consideredrepresentative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significantadditional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in theforward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similarrisks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. DuPontassumes no obligation to publicly provide revisions or updates to any forward looking statements, whether as a result of new information, future developments orotherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersignedhereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY(Registrant)

/s/ Jeanmarie F. DesmondJeanmarie F. Desmond

Vice President and Controller

March 31, 2017

E. I. DU PONT DE NEMOURS AND COMPANY

Exhibit Index Exhibit Number Description of Exhibit

2.1

Amendment No. 1, dated March 31, 2017, to the Agreement and Plan of Merger, dated as of December 11, 2015 by and among E. I. du Pont deNemours and Company, The Dow Chemical Company, Diamond Merger Sub, Inc., Orion Merger Sub, Inc. and Diamond-Orion HoldCo, Inc. (n/k/aDowDuPont Inc.)

99.1 Press Release, March 31, 2017, issued by E. I. du Pont de Nemours and Company.

99.2 Joint Press Release, March 31, 2017, issued by E. I. du Pont de Nemours and Company and The Dow Chemical Company.

99.3

Summary of Transactions with FMC: Divestiture of Certain Crop Protection Assets and Acquisition of FMC’s Health & Nutrition Business

Exhibit 2.1

AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER

This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “ Amendment ”), dated as of March 31, 2017, is by and among The DowChemical Company, a Delaware corporation (“ Dow ”), E. I. du Pont de Nemours and Company, a Delaware corporation (“ DuPont ”), DowDuPont Inc., aDelaware corporation f/k/a Diamond-Orion HoldCo, Inc. (“ DowDuPont ”), Diamond Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary ofDowDuPont (“ Diamond Merger Sub ”), and Orion Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of DowDuPont (“ Orion Merger Sub ”and, together with Diamond Merger Sub, the “ Merger Subs ”).

WHEREAS, Dow, DuPont, DowDuPont and the Merger Subs entered into that certain Agreement and Plan of Merger, dated as of December 11, 2015 (the “Merger Agreement ”);

WHEREAS, Dow, DuPont, DowDuPont and the Merger Subs now intend to amend certain provisions of the Merger Agreement as set forth herein; and

WHEREAS, the boards of directors (or a duly authorized committee thereof) of each of Dow, DuPont, DowDuPont, Diamond Merger Sub and Orion MergerSub have approved the execution and delivery of this Amendment on behalf of the applicable party hereto.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is herebyacknowledged, Dow, DuPont, DowDuPont and the Merger Subs hereby agree as follows:

SECTION 1. Defined Terms . Capitalized terms used herein that are not otherwise defined have the meanings set forth in the Merger Agreement.

SECTION 2. Amendments to Merger Agreement . The Merger Agreement is hereby amended as follows:

2.1 Section 8.1(b)(i) of the Merger Agreement shall be amended and restated in its entirety to read as follows:

if the Mergers shall not have been consummated by August 31, 2017; provided, that the right to terminate this Agreement pursuant to thisSection 8.1(b)(i) shall not be available to any party whose failure to perform any of its material obligations under this Agreement has been theprimary cause of, or primarily resulted in, the failure of the Mergers to be consummated by such time;

2.2 Section 6.3 of the Merger Agreement shall be amended by adding the following new Section 6.3(c) thereto:

Orion shall not, nor shall Orion permit any of its Subsidiaries to, propose, negotiate, commit, accept, consent to or effect, whether by consentdecree, hold separate order or otherwise, any H&N Divestiture Action (as such term is

defined in the FMC Transaction Agreement) that would not be required pursuant to Section 5.1 of the FMC Transaction Agreement (in eachcase, without giving effect to any amendment, modification or waiver of the FMC Transaction Agreement after the date hereof) without theprior mutual written consent of Diamond and Orion (each acting in their respective reasonable good faith judgment).

2.3 The Merger Agreement shall be amended by adding the following new Section 6.16 thereto:

FMC Transaction Agreement Amendments. In no event shall Orion amend, supplement or otherwise modify, or grant any waiver under,Section 5.1(b)(vi) of the FMC Transaction Agreement without the prior mutual written consent of Orion and Diamond (each acting in theirrespective reasonable good faith judgments).

2.4 Section 9.3 of the Merger Agreement shall be amended by adding the following new defined term thereto as Section 9.3(cc):

“ FMC Transaction Agreement ” means that certain Transaction Agreement, dated as of March 31, 2017, by and between Orion and FMCCorporation.

2.5 The HoldCo Bylaws, attached as Exhibit B to the Merger Agreement, shall be amended by adding the following new Article X thereto:

DuPont and Dow intend that the first step of the Company’s intended separation process will be the spin-off of the Materials Business SpinCo,assuming such sequencing would allow for the completion of all intended spin-offs (i.e., spin-off of the Materials Business SpinCo and spin-off of either the AgCo Business SpinCo or the Specialty Business SpinCo) within 18 months of closing of the Mergers and would notadversely impact the value of the intended spin-off transactions to the Company’s shareholders.

SECTION 3. Effect on Merger Agreement . Other than as specifically set forth herein, all other terms and provisions of the Merger Agreement shall remainunaffected by the terms of this Amendment, and shall continue in full force and effect.

SECTION 4. Severability . If any term or other provision of this Amendment is invalid, illegal or incapable of being enforced by any rule of law or publicpolicy, all other conditions and provisions of this Amendment shall nevertheless remain in full force and effect so long as either the economic or legal substance ofthe transactions contemplated hereby and by the Merger Agreement is not affected in any manner materially adverse to any party or such party waives its rightsunder this Section 4 with respect thereto. Upon a determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties heretoshall negotiate in good faith to modify this Amendment so as to effect the original intent of the parties as closely as possible to the fullest extent permitted byApplicable Law in an acceptable manner to the end that the transactions contemplated hereby and by the Merger Agreement are fulfilled to the extent possible.

2

SECTION 5. Headings . The headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning orinterpretation of this Amendment.

SECTION 6. Counterparts . This Amendment may be executed in two or more counterparts, all of which shall be considered one and the same agreementand shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties.

SECTION 7. Successors and Assigns . This Amendment shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and theirrespective successors and permitted assigns as provided in the Merger Agreement. Neither this Amendment nor any of the rights, interests or obligations under thisAmendment shall be assigned, in whole or in part, by operation of law or otherwise by any of the parties without the prior written consent of the other parties. Anypurported assignment in violation of the preceding sentence shall be void.

SECTION 8. Governing Law; Jurisdiction .

8.1 This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that mightotherwise govern under any applicable principles of conflicts of laws thereof.

8.2 In any action between the parties arising out of or relating to this Amendment, each of the parties (i) irrevocably and unconditionally consents andsubmits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware in and for New Castle County, Delaware; (ii) agrees that itwill not attempt to deny or defeat such jurisdiction by motion or other request for leave from such court; and (iii) agrees that it will not bring any such actionin any court other than the Court of Chancery for the State of Delaware in and for New Castle County, Delaware, or, if (and only if) such court finds it lackssubject matter jurisdiction, the Federal court of the United States of America sitting in Delaware, and appellate courts thereof.

[ RemainderofPageIntentionallyLeftBlank]

3

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first above written.

THE DOW CHEMICAL COMPANY

By: /s/ Andrew N. Liveris Name: Andrew N. Liveris Title: Chairman and Chief Executive Officer

[ SignaturePagetoAmendmentNo.1toAgreementandPlanofMerger]

E. I. DU PONT DE NEMOURS AND COMPANY

By: /s/ Edward D. Breen Name: Edward D. Breen Title: Chairman of the Board & CEO

[ SignaturePagetoAmendmentNo.1toAgreementandPlanofMerger]

DOWDUPONT INC.

By: /s/ Duncan Stuart Name: Duncan Stuart Title: Vice President and Secretary

By: /s/ Nicholas C. Fanandakis Name: Nicholas C. Fanandakis Title: Vice President and Treasurer

[ SignaturePagetoAmendmentNo.1toAgreementandPlanofMerger]

DIAMOND MERGER SUB, INC.

By: /s/ Duncan Stuart Name: Duncan Stuart Title: Vice President and Secretary

[ SignaturePagetoAmendmentNo.1toAgreementandPlanofMerger]

ORION MERGER SUB, INC.

By: /s/ Nicholas C. Fanandakis Name: Nicholas C. Fanandakis Title: Vice President and Treasurer

[ SignaturePagetoAmendmentNo.1toAgreementandPlanofMerger]

Exhibit 99.1

DuPont Announces Agreement with FMC

– DuPont to Divest a Portion of Its Crop Protection Business and Acquire FMC’s Health & Nutrition Business –

– Transaction Marks Meaningful Step Forward in Proposed DuPont and Dow Merger; Maintains Significant Strategic Value Creation Potential of MergerTransaction –

– Merger with Dow Now Expected to Close Between August 1 and September 1 –

Wilmington, DE — March 31, 2017 – DuPont (NYSE: DD) today announced that it has entered into a definitive agreement with FMC Corporation (NYSE: FMC)to divest a portion of DuPont’s Crop Protection business, including certain research and development capabilities, and to acquire substantially all of FMC’sHealth & Nutrition business. The transaction includes consideration to DuPont of $1.6 billion to reflect the difference in the value of the assets, including cash of$1.2 billion and working capital of $425 million. The divestiture will satisfy DuPont’s commitments to the European Commission in connection with itsconditional regulatory clearance of the merger with Dow.

“We believe this agreement is an excellent outcome that serves the best interests of all stakeholders, including our shareholders, customers and employees,” saidEdward D. Breen, chairman and chief executive officer of DuPont. “Our intended independent Agriculture company will continue to benefit from the combined,complementary strengths of DuPont and Dow, which will include greatly expanded offerings and a robust pipeline across seed germplasm, biotech traits, and cropprotection to provide greater choice and innovation to growers around the world. At the same time, we are significantly enhancing our Nutrition & Healthcapabilities, a key area of growth and opportunity for the intended independent Specialty Products company.

“This agreement with FMC is a win-win. It is pro-competitive; it advances the regulatory approval process; and it maintains the strategic logic and value creationpotential of our merger with Dow and the three independent companies we intend to create,” concluded Breen.

The merger transaction is still expected to generate cost synergies of approximately $3 billion and growth synergies of $1 billion.

Divestiture of Select DuPont Crop Protection Assets

Under the terms of the agreement, FMC will acquire DuPont’s Cereal Broadleaf Herbicides and Chewing Insecticides portfolios – including Rynaxypyr ® ,Cyazypyr ® and Indoxacarb. In addition, FMC will acquire the DuPont Crop Protection research and development pipeline and organization, excluding seedtreatment, nematicides, and late-stage R&D programs, which DuPont will continue to develop and bring to market, and excluding personnel needed to supportmarketed products and R&D programs that will remain with DuPont. The assets being divested generated revenues in 2016 of about $1.4 billion.

E. I. du Pont de Nemours and Company

Following the divestiture, the Agriculture division of the merged company will retain strong crop protection assets, including an excellent portfolio in corn and soybroadleaf and grass control, a robust cereal weed control portfolio, DuPont’s strong position in disease control, and Dow AgroSciences’ industry leading insecticideportfolio. With its continued strength in R&D, the combined Agriculture division will be well positioned to accelerate growth, leveraging strong pipelines in bothseeds and chemistry to serve growers around the world with a robust portfolio of innovative solutions, greater choice, and competitive price for value.

Acquisition of FMC Health & Nutrition Business

As part of the transaction agreement, DuPont will acquire FMC’s Health & Nutrition business, which generated more than $700 million in revenues in 2016 fromtwo main segments: texturants as food ingredients and pharmaceutical excipients. The business is highly complementary to DuPont’s existing Nutrition & Health(N&H) business with opportunity for growth synergies. By integrating FMC’s complementary Health & Nutrition business, DuPont will strengthen its N&Hcapabilities with broader offerings and an expanded footprint.

DuPont’s N&H business is a leader in the food ingredients industry, using renewably sourced raw materials to create a wide range of ingredients that foodmanufacturers use to provide safer, healthier, more affordable and nutritious food and beverages for consumers. This transaction strengthens DuPont’s access tokey ingredients for its systems and food texturants portfolio, enables the business to expand into the fast-growing pharma excipients space, and provides access tonew and complementary routes to market. As a result, DuPont N&H will be in a stronger position to drive growth, invest in R&D, and provide more products andsolutions to customers worldwide.

The transaction with FMC is expected to close in the fourth quarter of 2017, subject to the closing of the DuPont and Dow merger, in addition to other customaryclosing conditions, including regulatory approvals.

To accommodate the requirements of the FMC transaction, DuPont and Dow have amended the merger agreement to extend the “Outside Date” to August 31,2017, and the companies anticipate closing of the merger to occur between August 1, 2017 and September 1, 2017, subject to satisfaction of customary closingconditions, including receipt of regulatory approvals. The companies still expect the intended spin-offs to occur within 18 months after closing. In addition, Dowand DuPont are announcing that they now expect the first spin-off of the intended separation process will be the spin-off of the post-merger Material Sciencecompany.

Evercore and Goldman, Sachs & Co. are serving as DuPont’s financial advisors for the transaction, with Skadden, Arps, Slate, Meagher & Flom LLP acting as itslegal advisor.

DuPont will hold a conference call and webcast on Friday, Mar. 31, 2017, at 9:00 AM ET to discuss this news release. The webcast and additional presentationmaterials can be accessed by visiting the company’s investor website (Events & Presentations) at www.investors.dupont.com. A replay of the conference callwebcast will be available for 90 days by calling 1 (630) 652-3042, Passcode 6596503#. For additional information see the investor center athttp://www.dupont.com.

2

About DuPont

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and servicessince 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders, we can help find solutions to such globalchallenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additionalinformation about DuPont and its commitment to inclusive innovation, please visit www.dupont.com.

Contacts: Media InvestorsDan Turner Greg Friedmandaniel.a.turner@dupont.com greg.friedman@dupont.com+1 302-996-8372 +1 302-774-4994

Forward-Looking Statements:

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933,as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected futurebusiness and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,”“will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, todifferent degrees, uncertain, such as statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the“DowDuPont Merger”) and the proposed transaction with FMC and the anticipated benefits thereof. These and other forward-looking statements, including thefailure to consummate the DowDuPont Merger or the proposed transaction or to make or take any filing or other action required to consummate such transactionsin a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differmaterially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) thecompletion of the DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated taxtreatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition,losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s or the Health andNutrition business’s operations and other conditions to the completion of the DowDuPont Merger and the proposed transaction, (ii) the possibility that theDowDuPont Merger and the proposed transaction may not close, including because the various approvals, authorizations and declarations of non-objections fromcertain regulatory and governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely basis orotherwise, including that these regulatory or governmental authorities may not approve of FMC as an acceptable purchaser of the Ag business in connection withthe proposed transaction or may impose conditions on the granting of the various approvals, authorizations and declarations of non-objections, including requiringthe respective Dow, DuPont and FMC businesses, including the Health and Nutrition business (in the case of DuPont) and the Ag business (in the case of FMC),

3

to divest certain assets if necessary to obtain certain regulatory approvals or otherwise limiting the ability of the combined company to integrate parts of the Dowand DuPont businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to integrate the Health and Nutrition businesssuccessfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont Merger or the proposed transaction thatcould be instituted against DuPont or its directors, (v) the risk that disruptions from the DowDuPont Merger or the proposed transaction will harm DuPont’sbusiness, including current plans and operations, (vi) the ability of DuPont to retain and hire key personnel, (vii) potential adverse reactions or changes to businessrelationships resulting from the announcement or completion of the DowDuPont Merger or the proposed transaction, (viii) uncertainty as to the long-term value ofDowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory and economic developments,(xi) potential business uncertainty, including changes to existing business relationships, during the pendency of the DowDuPont Merger or the proposed transactionthat could affect DuPont’s financial performance, (xii) certain restrictions during the pendency of the DowDuPont Merger or the proposed transaction that mayimpact DuPont’s ability to pursue certain business opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including,but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well asother risks associated with the DowDuPont Merger or the proposed transaction, are or will be more fully discussed in (1) DuPont’s most recently filed Form 10-K,10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy statement/prospectus included in the RegistrationStatement filed with the SEC in connection with the DowDuPont Merger. While the list of factors presented here is, and the list of factors presented in the relevantForm 10-K, 10-Q and 8-K reports and the Registration Statement are, considered representative, no such list should be considered to be a complete statement of allpotential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences ofmaterial differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption,operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidatedfinancial condition, results of operations, credit rating or liquidity. DuPont assumes no obligation to publicly provide revisions or updates to any forward-lookingstatements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities andother applicable laws.

4

Exhibit 99.2

Dow and DuPont Announce Amendments to Transaction Merger Agreement

• DowandDuPontAmendMergerAgreementtoReflectExtensiontoAugust31;CloseofTransactionNowExpectedNoEarlierthanAugust1

• DowandDuPontReiterateIntendedSpin-offsWillOccurWithin18MonthsAfterClosing

• MaterialScienceCompanyNowExpectedtobetheFirstSpin-off

Wilmington, DE and Midland, MI — March 31, 2017 — DuPont (NYSE: DD) and Dow (NYSE: Dow) today announced several amendments to the companies’transaction agreement involving the proposed merger of equals and intended subsequent separation into three independent publicly traded companies.

To accommodate the requirements of DuPont’s recently announced transaction with FMC, Dow and DuPont have amended Section 8.1(b)(i) of the mergeragreement to extend the “Outside Date” definition to August 31, 2017 with anticipated closing of the transaction no earlier than August 1, 2017, subject tosatisfaction of customary closing conditions, including receipt of regulatory approvals.

DuPont’s transaction with FMC is expected to close in the fourth quarter of 2017, subject to the closing of the DuPont and Dow merger, in addition to othercustomary closing conditions, including regulatory approvals.

Dow and DuPont reiterate both companies’ expectations that the intended spinoffs will occur within 18 months after closing. In addition, Dow and DuPont nowexpect that the first spin-off in the intended separation process will be the spin-off of the post-merger Material Science Company.

The companies continue to expect the merger transaction to generate approximately $3 billion of cost synergies and $1 billion of growth synergies.

“This revised agreement was necessary and a very positive outcome driven by the transaction with FMC, announced by DuPont today. It is another significantmilestone in our progress to complete this value-creating transaction and the subsequent intended spins as swiftly as possible and without any change to thecommitted synergies,” said Andrew Liveris, chairman and chief executive officer of Dow.

“Today’s announced transaction enables us to satisfy the European Commission’s approval conditions, while maintaining the strategic logic and value creationpotential of our merger and the three independent companies we intend to create,” said Edward D. Breen, chairman and chief executive officer of DuPont.

ABOUT DOW

Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company is drivinginnovations that extract value from material, polymer, chemical and biological science to help address many of the world’s most challenging problems, such as theneed for fresh food, safer and more sustainable transportation, clean water, energy efficiency, more durable infrastructure, and increasing agricultural productivity.Dow’s integrated, market-driven portfolio delivers a broad range of technology-based products and solutions to customers in 175 countries and in high-growthsectors such as packaging, infrastructure, transportation, consumer care, electronics, and agriculture. In 2016, Dow had annual sales of $48 billion and employedapproximately 56,000 people worldwide. The Company’s more than 7,000 product families are manufactured at 189 sites in 34 countries across the globe.References to “Dow” or the “Company” mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More informationabout Dow can be found at www.dow.com.

ABOUT DUPONT

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and servicessince 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders, we can help find solutions to such globalchallenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additionalinformation about DuPont and its commitment to inclusive innovation, please visit www.dupont.com.

Contact Information Dow Contacts DuPont Contacts

InvestorsNeal Sheoreynrsheorey@dow.com+1 989-636-6347

InvestorsGreg Friedmangreg.friedman@dupont.com+1 302-774-4994

MediaRachelle Schikorraryschikorra@dow.com+1 989-638-4090

MediaDan Turnerdaniel.a.turner@dupont.com+1 302-996-8372

Cautionary Notes on Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933,as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected futurebusiness and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,”“will,” “would,” “target,” similar

expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such asstatements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements, including thefailure to consummate the proposed transaction or to make or take any filing or other action required to consummate such transaction on a timely matter or at all,are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed inany forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) the completion of the proposedtransaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures,revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies forthe management, expansion and growth of the new combined company’s operations and other conditions to the completion of the merger, (ii) the ability of Dowand DuPont to integrate the business successfully and to achieve anticipated synergies, risks and costs and pursuit and/or implementation of the potentialseparations, including anticipated timing, any changes to the configuration of businesses included in the potential separation if implemented, (iii) the intendedseparation of the agriculture, material science and specialty products businesses of the combined company post-mergers in one or more tax efficient transactions onanticipated terms and timing, including a number of conditions which could delay, prevent or otherwise adversely affect the proposed transactions, includingpossible issues or delays in obtaining required regulatory approvals or clearances, disruptions in the financial markets or other potential barriers, (iv) potentiallitigation relating to the proposed transaction that could be instituted against Dow, DuPont or their respective directors, (v) the risk that disruptions from theproposed transaction will harm Dow’s or DuPont’s business, including current plans and operations, (vi) the ability of Dow or DuPont to retain and hire keypersonnel, (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger, (viii) uncertainty asto the long-term value of DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory andeconomic developments, (xi) potential business uncertainty, including changes to existing business relationships, during the pendency of the merger that couldaffect Dow’s and/or DuPont’s financial performance, (xii) certain restrictions during the pendency of the merger that may impact Dow’s or DuPont’s ability topursue certain business opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts ofterrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associatedwith the proposed merger, are more fully discussed in the joint proxy statement/prospectus included in the Registration Statement filed with the SEC in connectionwith the proposed merger. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative,no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles tothe realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statementscould include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could havea material adverse effect on Dow’s or DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. Neither Dow nor DuPont assumesany obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments orotherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

###

Summary of Transactions with FMC: Divestiture of Certain Crop Protection Assets and Acquisition of FMC’s Health & Nutrition Business 1 March 31, 2017 Exhibit 99.3

Cautionary Notes on Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the “DowDuPont Merger”) and the proposed transaction with FMC Corporation (FMC) and the anticipated benefits thereof. These and other forward-looking statements, including the failure to consummate the DowDuPont Merger or the proposed transaction or to make or take any filing or other action required to consummate such transactions in a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) the completion of the DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s or the Health and Nutrition business’s operations and other conditions to the completion of the DowDuPont Merger and the proposed transaction, (ii) the possibility that the DowDuPont Merger and the proposedtransaction may not close, including because the various approvals, authorizations and declarations of non-objections from certain regulatory and governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely basis or otherwise, including that these regulatory or governmental authorities may not approve of FMC as an acceptable purchaser of the Ag business in connection with the proposed transaction or may impose conditions on the granting of the various approvals, authorizations and declarations of non-objections, including requiring the respective Dow, DuPont and FMC businesses, including the Health and Nutrition business (in the case of DuPont) and the Ag business (in the case of FMC), to divest certain assets if necessary to obtain certain regulatory approvals or otherwise limiting the ability of the combined company to integrate parts of the Dow and DuPont businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to integrate the Health and Nutrition business successfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont Merger or the proposed transaction that could be instituted against DuPont or its directors, (v) the risk that disruptions from the

Cautionary Notes on Forward Looking Statements, Continued DowDuPont Merger or the proposed transaction will harm DuPont’s business, including current plans and operations, (vi) the ability of DuPont to retain and hire key personnel, (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the DowDuPont Merger or the proposed transaction, (viii) uncertainty as to the long-term value of DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory and economic developments, (xi) potential business uncertainty, including changes to existing business relationships, during the pendency of the DowDuPont Merger or the proposed transaction that could affect DuPont’s financial performance, (xii) certain restrictions during the pendency of the DowDuPont Merger or the proposed transaction that may impact DuPont’s ability to pursue certain business opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the DowDuPont Merger or the proposed transaction, are or will be more fully discussed in (1) DuPont’s most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy statement/prospectus included in the Registration Statement filed with the SEC in connection with the DowDuPont Merger. While the list of factors presented here is, and the list of factors presented in the relevant Form 10-K, 10-Q and 8-K reports and the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statementscould include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. DuPont assumes no obligation to publicly provide revisions or updates to any forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Adjusted EBITDA Financial Information This document includes financial information described as “Adjusted EBITDA”, which is a financial term based on earnings before interest, taxes, depreciation and amortization. Adjusted EBTIDA does not conform to U.S. generally accepted accounting principles (GAAP) and is considered a non-GAAP measure. The Adjusted EBITDA presented represents management’s best estimate of 2016 financial performance for the portion of DuPont’s business to be divested inclusive of certain assumptions regarding allocations of costs and therefore a directly comparable measure that would be considered calculated and presented in accordance with GAAP is not available.

DuPont to sell cereal broadleaf herbicides and chewing insecticides, together with certain crop protection R&D capabilities and early stage pipeline initiatives to FMC Corporation ("FMC") DuPont to acquire substantially all of FMC’s Health & Nutrition business, including food ingredients and pharmaceutical excipients DuPont to receive $1.6B from FMC reflecting difference in asset value; $1.2B in cash, $0.4B in working capital Transactions contingent on DowDuPont merger of equals Significant progress on DowDuPont merger of equals Targeted merger to close by August 31, 2017 Targeted close of transactions with FMC in 4Q 2017 ~$3B of expected DowDuPont merger cost synergies and $1B of growth synergies preserved Summary of Transactions1 FMC Health & Nutrition 2016 Sales: $707MM 2016 Adjusted EBITDA2: $228MM Select Herbicides Select Insecticides Certain Crop Protection R&D Capabilities and Early Stage Discovery Pipeline 2016 Sales: ~$1.4B 2016 Adjusted EBITDA3: ~$450MM 1 Subject to satisfaction of closing conditions, including receipt of regulatory approval 2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization. 3 Adjusted EBITDA represents management’s estimate of 2016 earnings for the product lines and R&D organization and pipeline, including certain allocations, to be divested before interest, taxes, depreciation & amortization. $1.625B = Difference in asset value

DowDuPont’s Strong Global Pure-Play Agriculture Business DuPont Agriculture Planned Divestiture 2016 Sales $1.4B 1Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings. 2 Late stage defined as pipeline in the following phases: (3) Advanced Development, (4) Pre-Launch, and (L) Launch, as outlined in the presentation at the Bank of America Merrill Lynch conference on March 1, 2017. Agriculture Business Before Planned Divestiture 2016 Net Sales1: $15.7B Agriculture Business After Planned Divestiture 2016 Net Sales1: $14.3B DowDuPont’s Agriculture Business Will Have: A strong, balanced, pure-play profile with a comprehensive and diverse seed, trait, and crop protection portfolio and exceptional growth opportunity Strong IP-protected portfolio of crop protection assets, including insect control, cereal weed control, broadleaf and grass control, and disease control Industry-leading soy and corn selective herbicide offering and strong market share position in cereal crops Integrated approach to increase crop productivity by leveraging innovative technologies on a foundation of agronomic, biotechnology, and digital solutions Enhanced scale, multiple routes-to-market enabling deeper customer intimacy and delivery of complete crop productivity solutions Planned Divestiture to Include: DuPont’s cereal broadleaf herbicides portfolio DuPont’s chewing insecticides portfolio: Rynaxypyr®, Cyazypyr® and Indoxacarb DuPont’s Crop Protection research and development pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs1, which DuPont will continue to develop and bring to market, and excluding personnel needed to support marketed products and R&D programs that will remain with DuPont

ü 1. This product is fully approved in the U.S. and Canada. Traits included in these products may or may not be approved in all global markets. Combination Creates Step-Change Capability to Drive Crop Productivity Strong portfolio of seed and crop protection solutions to increase grower profitability Crop Protection Germplasm / Traits Seed Brands Traits Insecticides Herbicides Fungicides Other Offerings Advanced Technologies Specialty Insect Control Portfolio 1 ü ü Planned divestiture maintains the strategic logic and value creation potential of the merger Broad Seed Offering to Drive Yield Improvements Leading seed portfolio based on elite germplasm delivered through traditional and advanced breeding techniques Strong, diverse trait offerings Innovative Crop Protection Portfolio Broad portfolio of herbicide, insecticide, and fungicide offerings Comprehensive pipeline addressing global resistance Leadership position in diverse markets globally Expanding Portfolio of Diverse Technologies Robust seed treatment offering leveraging seed, crop protection and development expertise Prominent digital ag offering providing solid grower returns

High-margin, high-quality business exposed to attractive demographic macro tailwinds in Health & Nutrition Products for nutrition market providing texture, structure and physical stability solutions that thicken and stabilize food products Formulation ingredients serving the health excipient industry that function as binders, disintegrants and controlled-release compounds Complementary businesses with new opportunities for growth Greater offerings within DuPont’s existing texturants business; provides expertise in key areas such as cellulosics and expanded raw material access Diversifies DuPont’s N&H portfolio via addition of pharmaceutical excipients platform; brings market and customer access to pharmaceutical industry Creates opportunities for incremental synergies for Specialty Products Transaction Strengthens DowDuPont’s Innovation-Driven Specialty Products Platform 2016 Net Sales1 FMC Health & Nutrition2 Nutrition Ingredients Health Excipients ~$0.7B Functional Health Ingredients ~$0.2B EBITDA Electronics & Communications Industrial Biosciences Protection Solutions Nutrition & Health ~$3B Aramids Nonwovens Solid Surfaces ~$1.5B Enzymes Biomaterials ~$4B Nutrition Health FMC H&N Process Technologies 1 Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings. 2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization. ~$4B

Specialty Products to Capitalize on Global Megatrends to Deliver Organic Growth Across Portfolio Resulting in the need for… Engineered materials that protect people, processes and the environment Biotechnology solutions for large-scale industrial processes Key Global Megatrends Leading Positions Aramid fibers and paper Nonwoven films and fabrics Protective garments Industrial enzymes Advanced biofuels Sulfuric acid technology Electronic materials that enable miniaturization, connectivity and versatility Solar PV materials Circuit packaging materials Semicon fab materials Safe, nutritious and healthy foods Probiotics & cultures Systems and texturants Specialty proteins Electronics & Communications Industrial Biosciences Protection Solutions Nutrition & Health Connectivity and functionality Protection and sustainable development Emerging needs in new geographies Improved health and nutrition Renewable energy and materials

Copyright © 2017 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and all products, unless otherwise noted, denoted with ® or TM are trademarks or registered trademarks of E. I. du Pont de Nemours and Company. +Images reproduced by E. I. du Pont de Nemours and Company under license from the National Geographic Society.